research Recent Approaches of Antibody Therapeutics in Androgenetic Alopecia
Antibody treatments show promise for hair loss but need more research.
Search
forLearn
0 / 0 results — no results
Research
5 / 357 results 
research Monoclonal Antibody Against Prolactin Receptor: A Randomized Placebo-Controlled Study Evaluating Safety, Tolerability, and Pharmacokinetics of Repeated Subcutaneous Administrations in Postmenopausal Women
The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research Effects of Long-Term Treatment With Finasteride (MK-906), a 5-Alpha Reductase Inhibitor, on Circulating LH, FSH, Prolactin, and Estradiol
Finasteride safely lowers DHT levels without affecting hormone levels, helping with conditions like enlarged prostate, acne, and hair loss.
research Drug Repurposing: Hypothesis, Molecular Aspects, and Therapeutic Applications
Drug repurposing is a cost-effective way to find new uses for existing drugs, speeding up treatment development.
Community Join
5 / 14 resultscommunity All Drugs in Clinical Trials in 2023
12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.
community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community Since there is so much hype for cosmeRNA and HMI-115...
Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.